Lancet. 1995 May 20;345(8960):1274-5.
We examined the relation between the risk of major coronary events (coronary death and non-fatal myocardial infarction) and baseline cholesterol levels in patients with coronary heart disease, randomised to placebo or simvastatin therapy in the Scandinavian Simvastatin Survival Study (4S). The relative risk reduction in the simvastatin group was 35% (95% CI 15-50) in the lowest quartile of baseline low-density-lipoprotein cholesterol and 36% (19-49) in the highest. Simvastatin significantly reduced the risk of major coronary events in all quartiles of baseline total, high-density-lipoprotein, and low-density-lipoprotein cholesterol, by a similar amount in each quartile.
在斯堪的纳维亚辛伐他汀生存研究（4S）中，我们研究了冠心病患者随机接受安慰剂或辛伐他汀治疗时，主要冠状动脉事件（冠状动脉死亡和非致命性心肌梗死）风险与基线胆固醇水平之间的关系。在基线低密度脂蛋白胆固醇最低四分位数组中，辛伐他汀组的相对风险降低了35%（95%可信区间15 - 50），在最高四分位数组中降低了36%（19 - 49）。在基线总胆固醇、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇的所有四分位数组中，辛伐他汀均显著降低了主要冠状动脉事件的风险，且在每个四分位数组中降低幅度相似。
